Insulin Degludec and Albuterol Interaction

Understanding the Insulin Degludec and Albuterol Interaction

FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Insulin Degludec belongs to the Ultra-Long-Acting Insulin class and Albuterol belongs to the Short-Acting Beta-2 Agonist class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Albuterol can decrease the blood-sugar-lowering effect of insulin. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Insulin Degludec has 12 total documented interactions on file in this dataset, and Albuterol has 16. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Monitor your blood sugar levels closely if you are using albuterol. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Insulin Degludec or Albuterol based on a web page, speak with your prescriber or pharmacist before making any change.